The Pharmaceutical Benefits Advisory Committee (PBAC) recommended amending the Pharmaceutical Benefits Scheme (PBS) eligibility criteria for both COVID-19 medicines molnupiravir (Lagevrio^®) and nirmatrelvir and ritonavir (Paxlovid^®) to be method-agnostic with regards to nucleic acid testing for respiratory pathogen detection. The PBAC Outcome Statement and updates to the molnupiravir (Lagevrio®) and nirmatrelvir and ritonavir (Paxlovid®) Fact sheets are now available.